Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 30;8:11393. doi: 10.1038/s41598-018-29845-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of mutEphA4-Fc treatment on SOD1^G93A mice in functional tests and disease onset. (A) Kaplan Meier plot of ages (in days) of mutEphA4-Fc treated and saline control groups, in which the animal reached its peak body weight. The mean disease onset in the mutEphA4-Fc-treated group was delayed by about one week, compared with that in the saline control group; however, this difference was not statistically significance (log-rank test; p = 0.15). (B) Rotarod test values for mutEphA4-Fc treated and saline control groups show better performance of the mutEphA4-Fc treatment group from week 17 to week 23, compared with the control group (n = 8 per group; two-way ANOVA with Fisher’s LSD test at each age; *p < 0.05; **p < 0.01; ***p < 0.001). (C) Hind-limb grip strength; significant improvements in grip strength are seen in mutEphA4-Fc-treated SOD1^G93A mice versus saline-treated mice at 9 weeks and 18–21 weeks of age. (two-way ANOVA with Fisher’s LSD test at each age; *p < 0.05; ***p < 0.001). (D) Kaplan Meier plot of survival time (in days) of mutEphA4-Fc-treated and saline control groups. The mutEphA4-Fc treatment group displayed a longer median survival time compared with the control group; however, this difference was not statistically significant. (log-rank test; p = 0.19). Data are expressed as mean ± SEM; n = 8 per group.